The causes and management of endometrial breakthrough bleeding

Reproductive Medicine Review

Volumn 9, Issue 2, 2001, Pages 153-171

  Hickey, M ^a   Fraser, I S ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANGIOGENESIS INHIBITOR; ANTIGESTAGEN; CYTOKINE; DOXYCYCLINE; ETONOGESTREL; FLAVONOID; GAMMA INTERFERON; GESTAGEN; LEVONORGESTREL; LOW DOSE ORAL CONTRACEPTIVE; MATRIX METALLOPROTEINASE; MIFEPRISTONE; NOMEGESTROL ACETATE; ONAPRISTONE; RALOXIFENE; SEX HORMONE; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

AMENORRHEA; BREAKTHROUGH BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG EFFICACY; ENDOMETRIUM; ENZYME ACTIVATION; FEMALE; HEMOSTASIS; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; HYSTEROSCOPY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYMPTOM; VAGINA BLEEDING;

EID: 0035723988     PISSN: 09622799     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0962279901000254     Document Type: Review

References (100)

1. Norplant consensus statement and background review
2. Findings in Phase III studies of norplant implants
3. Vaginal bleeding disturbances and implantable contraceptives
4. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception
5. The associated between vaginal bleeding patterns and reasons for discontinuation of contraceptive use
6. Women's opinion on withdrawal bleeding on hormone replacement therapy
7. Women's expectations and acceptance of cyclic induced HRT bleeds
8. Regular bleeding on hormone replacement therapy: A myth?
9. What women want from hormone replacement therapy: Results of an international survey
10. HRT and irregular bleeding
11. Endometrial bleeding in hormone replacement therapy users: Preliminary findings regarding the role of matrix metalloproteinase 9 (MMP-9) and tissue inhibitors of MMPs
12. Management of vaginal bleeding irregularities induced by progestin-only contraception
13. A qualitative study of perceptions, attitudes, and experiences of long-term levonorgestrel implant users
14. Risk factors for HIV-1 infection in adults in a rural Ugandan community: A case-control study
15. Sexual intercourse during menstruation and self-reported sexually transmitted disease history among women
16. Use of Norplant implants in asymptomatic HIV-1 infected women
17. Condom practices of urban teens using Norplant contraceptive implants, oral contraceptives, and condoms for contraception
18. Steroids and endometrial breakthrough bleeding: Future directions for research
19. Hormonal contraception and bleeding disturbances: A clinical overview
20. The endometrial vascular appearance in Norplant users: Preliminary results from an hysteroscopic study
21. Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding
22. Menstruation
23. Menstruation in intraocular endometrial transplants in the rhesus monkey. Contributions to embryology
24. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. VI. Comparison of retinal and cerebral cortex metabolism, and effects of antioxidant therapy
25. Endometrial morphology during the normal cycle and under the influence of contraceptive steroids
26. A comparison of mechanisms underlying disturbances of bleeding caused by spontaneous dysfunctional uterine bleeding or hormonal contraception
27. Changes in endothelial cell basement membrane in Norplant users
28. Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-2 contraception
29. Pericytes: Cell biology and pathology
30. Perivascular smooth muscle α-actin is reduced in the endometrium of women with progestin-only contraceptive breakthrough bleeding
31. Electron microscopic and immunohistochemical investigation of Reinke's edema
32. The role of hyperoxia in the aetiology of retinopathy of prematurity
33. Histopathology of diabetic retinopathy in man
34. Vascular endothelial growth factor/vascular permeability factor in a mouse model of retinal neovascularization
35. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis
36. Angiogenesis
37. The effect of high dose medium and long-term progestogen exposure on endometrial vessels
38. Precise measurements of intrauterine vascular structures at hysteroscopy in menorrhagia and during Norplant use
39. Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel
40. Changes in endometrial vascular density in Norplant users
41. Angiogenesis in embryos and ischaemic disease
42. Tumour vascular permeability factor stimulated endothelial cell growth and angiogenesis
43. Vascular permeability factor, an endothelial cell mitogen related to PGDF
44. Vascular endothelial growth factor is a secreted endothelial cell mitogen
45. Angiogenesis, vascular endothelial growth factor and the endometrium
46. Vascular permeability factor; a tumor derived polypeptide that induced endothelial cell and monocyte procoagulation activity and promotes monocyte migration
47. The potential role of tissue factor in regulating haemostasis, thrombosis and angiogenesis in human endometrium
48. Lack of correlation between vascular endothelial growth factor production and endothelial cell proliferation in the human endometrium
49. Ovarian steroids and cytokine modulation of human endometrial angiogenesis
50. The effects of levonorgestrel implants on vascular endothelial growth factor expression in the endometrium
51. The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium
52. Cytokine expression in human endometrium throughout the menstrual cycle
53. Expression of tumor necrosis factor-alpha and its mRNA in the endometrial mucosa during the menstrual cycle
54. Site and menstrual cycle-dependent expression of proteins of the tumor necrosis factor (TNF) receptor family and BCL-2 oncoprotein and phase specific production of TNF-alpha in human endometrium
55. Localisation of T cells, interferon-gamma and HLA-DR in eutopic and ectopic human endometrium
56. Antiproliferative effect of interferon-gamma in human endometrial epithelial cells in vitro: Potential local growth modulatory role in the endometrium
57. Endometrial leukocytes and menstruation
58. Vascular and cellular changes in the decidualized endometrium of the ovariectomized mouse following cessation of hormone treatment: A possible model for menstruation
59. Effect of high-dose progestogens on white cells and necrosis in human endometrium
60. Endometrial lymphomyeloid cells in abnormal uterine bleeding due to levonorgestrel (Norplant)
61. MMP leukocytes and steroid-associated uterine bleeding
62. Focal cellular origin and regulation of interstitial collagenase (MMP-1) are related to menstrual breakdown in human endometrium
63. The expression of interstitial collagenase in human endometrium is controlled by progesterone and by oestradiol and is related to menstruation
64. Matrix metalloproteinases in normal menstruation
65. Menstruation induction by matrix metalloproteinases and inflammatory cells
66. Regulation of matrix metalloproteinase-9 in endometrium during the menstrual cycle and following administration of intrauterine levonorgestrel
67. Endometrial breakdown in women using Norplant is associated with migratory cells expressing matrix metalloproteinase-9
68. Functions of lysosomes
69. Haemostasis in menstrual endometrium: A review
70. Lysosomal concept of menstrual bleeding in humans
71. Monitoring of hormone replacement therapy in postmenopausal women by transvaginal sonography and color flow Doppler: Study in different phases of sequential therapy
72. Endometrial blood flow measured by xenon-133 clearance in women with normal menstrual cycles and dysfunctional uterine bleeding
73. The measurement of endometrial perfusion in Norplant users: A pilot study
74. Prolonged hypoxia alters endothelial barrier function
75. Angiogenesis
76. Immunohistochemical sex steroid receptor distribution in endometrium from long-term subdermal levonorgestrel users and during the normal menstrual cycle
77. Expression of progesterone receptor mRNA in the endometrium during the normal menstrual cycle and in Norplant users
78. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system
79. Intrauterine progestin induces continuous insulin-like growth factor-binding protein-1 production in the human endometrium
80. The morphological response of blood vessels of the endometrium to low dose oral norethisterone and levonorgestrel
81. Immunolocalisation of endothelin and neutral endopeptidase in the endometrium of users of subdermally implanted levonorgestrel (Norplant)
82. Endometrial endothelin: Regulator of uterine bleeding and endometrial repair
83. Junctional barrier complexes undergo major alterations during plasma membrane transformation of uterine epithelial cells
84. A survey of different attitudes to the management of menstrual disturbance in women using injectable contraceptives
85. Basement membrane proteins: Molecular structure and function
86. TGF-beta increases retinal endothelial cell permeability by increasing MMP-9: Possible role of glial cells in endothelial barrier function
87. A double-blind placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility
88. Oxidative stress, vitamin E and progestin breakthrough bleeding
89. Chronic antiprogestin therapy produces a stable atrophic endometrium with decreased fibroblast growth factor: A one year primate study on contraception and amenorrhoea
90. Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands in vivo
91. Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium
92. Development of matrix metalloproteinase inhibitors in cancer therapy
93. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease
94. In vivo inhibition of human neutrophil collagenase (MMP-8) activity during long-term combination therapy of doxycycline and non-steroidal anti-inflammatory drugs (NSAID) in acute reactive arthritis
95. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms
96. Effect of inhibition of matrix metalloproteinases on endometrial decidualization and implantation in mated rats
97. Cytokeratins 8, 18 and 19 in endometrial epithelial cells during the normal menstrual cycle and in women receiving Norplant
98. The role of selective oestrogen receptor modulators in the treatment of endometrial bleeding in women using long-acting progestin contraception
99. Once monthly antiprogestin controls menstrual bleeding during progestin-only contraception in primates
100. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles